Hepatit B dışı endikasyonla anti-hbc pozitif donörlerden yapılan karaciğer transplantasyonu sonrası alıcılarda de novo hepatit b enfeksiyonu gelişiminin retrospektif araştırılması
Küçük Resim Yok
Tarih
2019
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
İnönü Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Giriş: Çalışmamızın amacı, hepatit B dışı endikasyonla anti-HBc pozitif donörlerden yapılan karaciğer transplantasyonu sonrası alıcılarda de novo hepatit B enfeksiyonu gelişiminin retrospektif araştırılmasıdır. Material ve Metodlar: İnönü Üniversitesi Turgut Özal Tıp Merkezi Gastroenteroloji Bilim Dalında Ocak 2007 ile Aralık 2018 tarihleri arasında, hepatit B dışı endikasyonla anti-HBc pozitif donörlerden karaciğer transplantasyonu yapılan 46 hastanın verileri retrospektif olarak incelendi. Bulgular: HBsAg negatif hastalara anti-HBc pozitif donörlerden karaciğer nakli yapılan 46 hastadan 8 (%17.4) hastaya karaciğer nakli sonrası profilaktik antiviral tedavi verildiği, 38 (%82.6) hastaya ise profilaktik antiviral tedavi verilmeden takip edildiği saptandı. Profilaktik antiviral tedavi alan hiçbir hastada de novo hepatit B enfeksiyonu gelişmezken (%0), profilaktik antiviral tedavi almayan 38 hastadan 11 hastada (%28.9) de novo hepatit B enfeksiyonu geliştiği belirlendi. Profilaktik antiviral tedavi almayan hastalardan anti-HBc ve anti-HBs negatifliği olan hastalardaki de novo hepatit B enfeksiyonu gelişme sıklığı (%63.6), anti-HBc ve/veya anti-HBs pozitifliği olan hastalara (%14.8) göre istatistiksel olarak anlamlı şekilde daha yüksekti. Sonuç: Sonuçlarımız, anti-HBc pozitif donörlerden yapılan karaciğer transplantasyonu sonrası alıcılarda profilaktik antiviral tedavinin ve hepatit B bağışıklığının de novo hepatit B enfeksiyonu gelişimini çok anlamlı şekilde önlediğini düşündürmektedir. Anahtar Kelime: De novo Hepatit B enfeksiyonu, anti-HBc pozitif donör, karaciğer nakli.
Introduction: The aim of our study was to retrospectively investigate the development of de novo Hepatitis B infection in recipients after liver transplantation by anti-HBc positive donors with non-hepatitis B indication. Material and Method: Data of 46 patients who had liver transplantation with non-hepatitis B indication from anti-HBc positive donors in İnönü University Turgut Özal Medical Center Gastroenterology Department between January 2007 and December 2018 were examined retrospectively. Results: Of the 46 patients who underwent liver transplantation from anti-HBc positive donors to HBsAg negative patients, 8 (17.4%) patients were given prophylactic antiviral after liver transplantation, and the remaining 38 (82.6%) patients were followed up without prophylactic antiviral treatment. While de novo hepatitis B infection was not developed in any patient who received prophylactic antiviral treatment (0%), it occurred in 11 of 38 patients (28.9%) without prophylactic antiviral treatment. In patients without prophylactic antiviral treatment; the frequency of de novo hepatitis B infection in patients with anti-HBc and anti-HBs negativity (63.6%) was significantly higher than patients with anti-HBc and / or anti-HBs positivity (14.8%). Conclusion: Our results suggest that prophylactic antiviral therapy and hepatitis B immunity in recipients after liver transplantation from anti-HBc positive donors significantly prevent the development of de novo hepatitis B infection. Keywords: De novo Hepatitis B infection, anti-HBc positive donor, liver transplantation.
Introduction: The aim of our study was to retrospectively investigate the development of de novo Hepatitis B infection in recipients after liver transplantation by anti-HBc positive donors with non-hepatitis B indication. Material and Method: Data of 46 patients who had liver transplantation with non-hepatitis B indication from anti-HBc positive donors in İnönü University Turgut Özal Medical Center Gastroenterology Department between January 2007 and December 2018 were examined retrospectively. Results: Of the 46 patients who underwent liver transplantation from anti-HBc positive donors to HBsAg negative patients, 8 (17.4%) patients were given prophylactic antiviral after liver transplantation, and the remaining 38 (82.6%) patients were followed up without prophylactic antiviral treatment. While de novo hepatitis B infection was not developed in any patient who received prophylactic antiviral treatment (0%), it occurred in 11 of 38 patients (28.9%) without prophylactic antiviral treatment. In patients without prophylactic antiviral treatment; the frequency of de novo hepatitis B infection in patients with anti-HBc and anti-HBs negativity (63.6%) was significantly higher than patients with anti-HBc and / or anti-HBs positivity (14.8%). Conclusion: Our results suggest that prophylactic antiviral therapy and hepatitis B immunity in recipients after liver transplantation from anti-HBc positive donors significantly prevent the development of de novo hepatitis B infection. Keywords: De novo Hepatitis B infection, anti-HBc positive donor, liver transplantation.
Açıklama
Anahtar Kelimeler
Gastroenteroloji, Gastroenterology
